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ABSTRACT
Introduction: Lung cancer is the most common
cancer worldwide, with 1.3 million new cases
diagnosed every year. It has one of the lowest survival
outcomes of any cancer because over two-thirds of
patients are diagnosed when curative treatment is not
possible. International research has focused on
screening and community interventions to promote
earlier presentation to a healthcare provider to improve
early lung cancer detection. This paper describes the
protocol for a phase II, multisite, randomised
controlled trial, for patients at increased risk of lung
cancer in the primary care setting, to facilitate early
presentation with symptoms of lung cancer.
Methods/analysis: The intervention is based on a
previous Scottish CHEST Trial that comprised of a
primary-care nurse consultation to discuss and
implement a self-help manual, followed by self-
monitoring reminders to improve symptom appraisal
and encourage help-seeking in patients at increased
risk of lung cancer. We aim to recruit 550 patients
from two Australian states: Western Australia and
Victoria. Patients will be randomised to the Intervention
(a health consultation involving a self-help manual,
monthly prompts and spirometry) or Control
(spirometry followed by usual care). Eligible
participants are long-term smokers with at least 20
pack years, aged 55 and over, including ex-smokers if
their cessation date was less than 15 years ago. The
primary outcome is consultation rate for respiratory
symptoms.
Ethics and dissemination: Ethical approval has
been obtained from The University of Western
Australia’s Human Research Ethics Committee (RA/4/1/
6018) and The University of Melbourne Human
Research Committee (1 441 433). A summary of the
results will be disseminated to participants and we
plan to publish the main trial outcomes in a single
paper. Further publications are anticipated after further
data analysis. Findings will be presented at national
and international conferences from late 2016.
Trial registration number: Australian New Zealand
Clinical Trial Registry ACTRN 1261300039 3752.
INTRODUCTION
Lung cancer is the commonest cancer world-
wide;1 in Australia, there were 11 280 new
cases and 8099 deaths due to lung cancer in
2010, making it the leading cause of cancer
death.2 Lung cancer ranks second for men
and fourth for women when considering all
causes of death. This reflects its relatively
high incidence (58 per 100 000 for males
and 31 per 100 000 for females), which is
still rising in women, and its low relative sur-
vival, only 7.8% of males and 9.3% of
females survive beyond 5 years.3 4
There is extensive literature spanning
several decades on the concept of ‘diagnostic
delay’ in cancer.5 6 This recognises that
patient pathways to presentation to health-
care and initial management in primary care
are key determinants of cancer patient out-
comes.7 8 Much of the research on cancer
diagnostic delay has suffered from lack of a
theoretical model and precise definitions of
key time points along the diagnostic pathway.
Walter et al9 published a systematic review of
cancer diagnostic studies that applied the
Andersen Model of Total Patient Delay.10 On
Strengths and limitations of this study
▪ The CHEST-Australia Trial represents the first
trial in Australia to test this type of intervention
and measure its impact on health care
consultations.
▪ The trial builds on preliminary evidence from the
Scottish CHEST Trial, which showed promising
results for altering symptom appraisal and help-
seeking behaviour.
▪ Information from this trial will enable planning of
a larger phase III international trial to further
assess the impact of the CHEST Intervention on
clinical outcomes.
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the basis of their review, they have modified this theoret-
ical framework, producing The Model of Pathways to
Treatment (figure 1).
The model proposes four key intervals:
1. The Appraisal Interval. The review found that the
nature of the symptoms was the most important
factor determining the duration of the Appraisal
Interval. Misattribution of symptoms either to a previ-
ous benign or concurrent condition or non-
recognition of the seriousness of symptoms contrib-
ute to longer Appraisal Intervals.11
2. The Help-Seeking Interval. Various factors may contrib-
ute to this interval including patient factors such as
competing events (eg, holidays), and emotional ones
such as fear. This includes fear of the consultation
and examination, or of the diagnosis and treat-
ment.12 Access to primary care and sanctioning help-
seeking by family or friends, so that patients do not
perceive themselves as wasting the doctor’s time, are
also important factors.12
3. The Diagnostic Interval. Depending on the healthcare
setting, this may involve a series of healthcare visits,
referrals and investigations, and often represents a
complex process. System factors including the role of
primary care as a gatekeeper, and access to investiga-
tions and specialist care, are key factors determining
this interval.9
4. The Pre-Treatment Interval. The time from formal
cancer diagnosis to initiation of treatment is also
strongly influenced by several healthcare system
factors such as access to staging investigations and
specialised treatments.
Several studies have explored symptom appraisal and
help-seeking in people recently diagnosed with lung
cancer. Two studies of lung cancer patients from
Western Australia have found that normalisation of
respiratory symptoms is very common with mean patient
delays to seek help of 47–80 days, respectively.13 14
Campbell and colleagues15 interviewed 360 Scottish
patients with lung cancer; of these, 50% had experi-
enced symptoms for more than 14 weeks before present-
ing to a doctor (median 99 days; IQR 31–381 days). The
duration of these patient delays should be compared
with reported lung cancer median volume doubling
times of 98 days.16 Factors associated with longer
symptom appraisal and help-seeking included living
alone, a history of chronic obstructive pulmonary
disease (COPD) and longer pack years of smoking. In
contrast, haemoptysis, new onset of shortness of breath
and cough were associated with earlier consulting.
Another English study had similar findings: most
patients recalled having symptoms for many months
before seeking help, but these symptoms were not recog-
nised as serious, were attributed to everyday causes, and
therefore not acted on.17 18 There was reluctance to
seek help among some people, partly because they were
unsure whether their symptoms were normal and, for
some, because of the stigma associated with smoking.
Furthermore, patients may not discuss all their symp-
toms of lung cancer when they do visit their general
practitioner (GP), suggesting patients need to be
empowered to recognise the significance of symptoms
and report them to healthcare providers.19 Patients may
also need clear guidance on reasons to revisit their GP if
their symptoms persist, an important safety-netting func-
tion of general practice.20
Further evidence for the potential to improve lung
cancer outcomes by earlier diagnosis comes from the US
Figure 1 Model of pathways to treatment.
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National Lung Cancer Screening Trial, which found a
20% relative reduction in lung cancer mortality from
annual low-dose CT.21 However, the uncertain cost-
effectiveness and feasibility of implementing national
lung cancer screening programmes means that other
approaches to timely diagnosis of lung cancer are still
needed. The search for useful biomarkers of lung
cancer shows promise, but is still at the validation
stage,22 suggesting an alternative strategy is to attempt to
diagnose lung cancer earlier through prompt recogni-
tion and investigation of symptoms suggestive of the
disease, particularly in those at higher risk.
Public awareness campaigns for educating patients on
symptom awareness have shown promise, but many have
limited reporting outcomes. Lung cancer ‘signs and
symptoms’ intervention studies such as ‘Show us your
lungs’ (Australia),23 ‘Be clear on Cancer (UK),24 ‘I’ll
tackle it soon’ (UK),25 aimed to raise awareness of the
signs and symptoms of lung cancer, and promote help
seeking behaviour. The ‘I’ll tackle it soon’ study showed
that a combined public awareness campaign and GP edu-
cation programme led to increased chest X-ray referrals
by 20% and lung cancer diagnoses by 27%.25
While patient level interventions show promise in
increasing cancer awareness,26 there has been limited
research on interventions delivered to individuals at
increased risk of lung cancer aimed at promoting earlier
presentation to healthcare. The Chest Trial in Scotland
was the first to show preliminary evidence that this
approach could alter consulting patterns in this popula-
tion.27 28 In this trial, a theoretically-based intervention,
which comprised of a primary-care nurse consultation to
discuss and implement a self-help manual, was tested,
followed by self-monitoring reminders. The key objec-
tives of the intervention were as follows, with the rele-
vant underlying theories in parentheses: (1) Increase
the salience and personal relevance of symptoms
(Illness Action Model29). (2) Improve knowledge of
symptoms by introducing chest disease prototypes
(Illness Action Model and Illness prototypes29 30). (3)
Reinforce the benefits of early intervention in lung
cancer and other chest disease (Theory of Planned
Behaviour31 32). (4) Sanction early consultation (Zola’s
triggers33). (5) Tackle barriers to consultation (Theory
of Planned Behaviour31 32). (6) Develop personalised
action and coping plans (Social Cognitive Theory and
Implementation Intentions).34 35 Intervention compo-
nents 1 and 2 aim to reduce the Symptom Appraisal
Interval, while components 3–6 aim to reduce the
Help-Seeking Interval. Based on consumer feedback the
intervention was designed specifically without any
mention of smoking cessation, which was seen as a
barrier to engagement. Furthermore, the focus was on
chest disease broadly, including the early detection of
lung cancer, COPD and other chronic respiratory condi-
tions. This was to reduce potential effects of fear and
nihilism surrounding lung cancer.36 Figure 2 presents a
summary of the intervention.
Two hundred and twelve people at increased risk of
lung cancer were recruited into the Scottish CHEST
Trial, of whom 206 completed the trial after 1 year of
follow-up (102 intervention, 104 control). The total con-
sultation rate was significantly higher in the intervention
group (adjusted consultation ratio 1.15, 95% CI 1.04 to
1.27 p=0.005) with a median number of consultations in
the year after intervention of 8 (IQR 4–11). The
adjusted consultation ratio for new chest symptoms also
increased but this did not reach statistical significance
(ratio 1.19, 95% CI 0.92 to 1.53). Participants in the
intervention group intended to consult sooner with
symptoms. There were non-significant increases in chest
X-ray requests and referrals to respiratory medicine in
the intervention group.27
The Scottish CHEST Trial therefore provides important
preliminary evidence for the potential efficacy of the inter-
vention in altering symptom appraisal and help-seeking
behaviour. However, stronger evidence is required before
this research can inform practice and policy. In particular,
evidence is required on the generalisability of the interven-
tion in other populations and the effect on clinical out-
comes as well as consulting behaviours.
Preliminary phase I research in Australia with con-
sumer focus groups was conducted to review the CHEST
self-help manual and provide feedback on the overall
intervention. In addition, the intervention was piloted
on 11 participants recruited from a general practice in
Perth, Western Australia. This work resulted in modifica-
tions to the language used in the consultation and self-
help manual, and led to the development of the CHEST
Australia Trial: a phase II, multisite, randomised con-
trolled trial that aims to test the modified CHEST
Intervention in an Australian population and measure
Figure 2 Intervention summary.
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the effect of the intervention on consultation rates for
chest symptoms.
METHODS AND ANALYSIS
The phase II trial is a multisite randomised controlled
trial. Those who meet the eligibility criteria and who
consent to participate are randomised 1:1 to either usual
care (control arm) or to the intervention (figure 3).
Randomisation is being performed using a centralised
independent tele-randomisation system managed by the
NHMRC Clinical Trials Centre, based at the University of
Sydney. Stratifying variables for randomisation are MRC
dyspnoea score (scores 1–3 and 4–5) and general practice
recruitment site.
Population and setting
Participants are being recruited from general practices
in Perth (Western Australia) and Melbourne (Victoria).
Recruitment began in May 2013 and aims to be com-
pleted in mid-2015.
Inclusion criteria
Eligible participants are long-term smokers with at least
20 pack years, aged 55 and over, including ex-smokers if
their cessation date was less than 15 years ago. This
represents a population at increased risk of lung
cancer.20 Participants are able to read and write English,
and to give informed consent.
Exclusion criteria
Exclusion criteria are severe psychiatric or cognitive dis-
order or previous diagnosis of lung cancer.
Participant and recruitment procedures
Smokers and ex-smokers are identified from practice
computerised records using a specific version of
Figure 3 Trial flowchart.
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electronic data extraction software, the ‘Canning tool’
(http://www.canningtool.com.au), developed for this
trial. Potentially eligible patients are invited to partici-
pate in the study by letter from their general practice.
The invitations include a patient information sheet,
‘expression of interest form’ and a consent form. The
expression of interest form asks four screening questions
aimed at assessing smoking pack years. These screening
questions provide more accurate information regarding
the eligibility of patients and overcome limitations of
electronic data on smoking in the medical record.
Non-responders are followed up after 2 weeks with a
reminder postcard. Eligible patients returning an expres-
sion of interest form are followed up by phone to make
an appointment with a health researcher at their
general practice. Randomisation is performed after com-
pletion of baseline data and informed consent has been
obtained.
Intervention
The Self-Help Manual, entitled ‘Chest Symptoms that
Call for Action’, is based around a simple action plan
logo, ‘It’s as easy as 1, 2, 3’. These three key actions are:
1. Look after number one and know the symptoms of
lung disease.
2. It takes two to tango: doctors can only help you if you
see them when you have symptoms.
3. Remember the 3-week rule and see your doctor if
you have symptoms for more than 3 weeks.
Participants randomised to the intervention arm have
their height, weight and spirometry (using an ‘Easy on
PC’; Niche Medical) measured at the consultation. The
results of the spirometry test are sent to the GP at the
end of the consultation. The trained researcher then
guides the patient through the self-help manual, which
is taken home by the participant. ‘If-then’ action plans
are developed during the consultation which is linked to
symptom checklists; ‘If-then’ coping plans are discussed
to tackle barriers to consultation. A range of monthly
self-monitoring prompts to appraise any current symp-
toms are tailored to individual preferences. These
include SMS and email reminders, postcards, phone
calls and fridge magnets. To ensure trial fidelity, inter-
vention consultations are recorded for quality assurance.
Control group
Participants randomised to the control arm attend a
consultation where they perform a spirometry test, and
follow-up procedures in the trial are discussed. There is
also a general discussion about lung health. This is
aimed as an attention control and to increase overall
engagement in the trial for control participants.
Participants then receive usual care at their general prac-
tice, including follow-up of abnormal spirometry.
Outcomes and measures
The primary outcome of this trial is consultation rates for
respiratory symptoms. Data on consultations in the year
before the trial and for 12 months after the consultation
will be collected through audit of GP records.
Additional outcomes include
1. Demographics and clinical variables. Age, gender,
marital status, postcode, highest education level,
occupation, MRC Dyspnoea Scale37 and lung func-
tion at baseline only.
2. Self-efficacy for consulting without delay. A 10-item self-
completed scale summed to score 10–100, devel-
oped for the Scottish CHEST Trial, which showed
good internal reliability (Cronbach α=0.85).
3. Knowledge of symptoms of lung disease. A 21-item self-
completed checklist of possible symptoms expressed
as a percentage correctly selected as associated with
chest disease.
4. Symptom appraisal and help-seeking intervals. This will
be measured using the SYMPTOM instrument (lung
cancer version), a self-completed questionnaire that
obtains data on presenting symptoms and their dur-
ation prior to consultation.38 This will be measured
monthly during the trial through electronic searches
of the GP records. If a consultation has occurred
about a respiratory symptom in that timeframe, the
participant is sent a SYMPTOM questionnaire to com-
plete about symptoms relating to that consultation.
5. Hospital anxiety and depression scale (HADS).39 This
14-item self-completed scale has been widely used to
measure distress, and has been extensively validated
and shown to perform well in a wide range of popu-
lations (mean Cronbach α=0.82; sensitivity and spe-
cificity 0.80).
6. Cancer-worry scale. A 6-item self-completed scale,
adapted from the breast cancer worry scale,40 which
showed good internal reliability in the CHEST Trial
(Cronbach α=0.88).
7. Quality of life will be measured using the AqoL-8d,34
a validated self-completed, multi-attribute utility
measure that can be used as part of the health eco-
nomic evaluation of the intervention. This 35-item
scale covers the following domains: independent
living, happiness, mental health, coping, relation-
ships, self-worth, pain and senses.
8. Heath service utilisation. In addition to the primary
measure of consultation rates for respiratory symp-
toms, data relating to total general practice consult-
ation rates, chest X-ray requests and referrals to
respiratory physicians, will also be captured through
audit of general practice records. Participants
consent to access to their Medicare claims data
(including pharmaceutical benefits scheme (PBS)
and Medicare benefits schedule (MBS)) through
the Department of Human Services. This will
provide more complete data relating to visits to
other general practices (and investigations and refer-
rals arising from these) as well as prescribing data.
9. Lung cancer incidence. This will be identified through
GP medical records, and by flagging participants
with the WA and Victorian Cancer Registries.
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10. Trial feasibility and acceptability. As a phase II trial we
will also obtain data on patient recruitment and
attrition, and response rates to outcome measures,
to inform decisions about a future phase III trial.
Measurement timing
The participant-completed measures (1–7 above) are
taken at baseline, 1 and 12 months, with the exception of
the SYMPTOM instrument, as already described. Health
service utilisation data will be collected at 12 months by
general practice medical record audit and accessing
Medicare and PBS data. This data will not be collected
for participants who formally withdraw from the trial.
Participant data and study management
All participants are allocated a unique identifying code.
Questionnaire data are entered into a custom built
Oracle database (on a secure server held at the
University of Western Australia) to allow scoring of the
measures in the questionnaire and enable patient track-
ing through the study.
Sample size and power calculation
Data from the Scottish trial was used to inform power
calculations.28 Assuming that the primary end point of
consultations for respiratory symptoms follows a Poisson
distribution, and that the expected average rate over
12 months in the study population will be 1.06 for
control patients and 25% higher for intervention
patients, a sample of 534 will provide at least 80% power
to reject the null hypothesis of no difference between
the groups at the two-sided 5% level of significance. The
primary end point will be measured from the medical
record audit, thus minimising attrition. Accounting for
the same attrition rate observed in the Scottish trial, we
require a total sample of 550 participants.
Analyses
All randomised patients will be considered eligible for
inclusion in the analysis in accordance with the inten-
tion to treat analysis principle. Appropriate methods for
dealing with missing end point data will be addressed
and informed by a blinded review of the data. The base-
line characteristics of the two arms will be described
using summary statistics. Possible consent bias will be
assessed by comparing demographic and clinical vari-
ables of participants against those who declined partici-
pation, and possible differential attrition will be assessed
by comparing baseline characteristics of those who with-
draw or die against those who remain in the study.
These comparisons will be performed using a two
sample t test (or non-parametric equivalent) for con-
tinuous variables and χ2 test for categorical variables.
The primary analysis will be a comparison between the
two groups on consultations rate for respiratory symp-
toms using a Poisson regression model, with general prac-
tice included as a factor. Comparisons between groups on
continuous secondary end points will be undertaken
using a linear model that includes general practice as a
factor and the baseline value as a covariate (where applic-
able). Comparisons between groups on categorical sec-
ondary end points will be performed using logistic
regression with general practice fitted as a factor. The
analyses performed on the primary and secondary end
points will be repeated adjusting for additional baseline
covariates (eg, number of consultations in 12 months
prior to randomisation, gender, comorbidities, smoking
status, MRC Dyspnoea Score) as part of a sensitivity ana-
lysis. Point estimates of the treatment effect will be pre-
sented with two-sided 95% CIs and two-sided p values.
Unadjusted p values from secondary analyses are inter-
preted in proper context and will be clearly labelled.
The health economic analysis estimates the cost of
CHEST minus any cost-savings due to avoided health-
care utilisation through early diagnosis. Benefits will be
extrapolated from the primary end points and via the
AQOL-8D quality of life questionnaire. Results will be
presented in terms of the incremental cost-effectiveness
ratio. Many of these model parameters will not be
powered for statistical significance. Therefore, mean esti-
mates of resource utilisation will be used and CIs are
generated by boot-strapping the data. Uncertainty will
be explored using probabilistic sensitivity analysis.
The CHEST-Australia Trial represents the first trial in
Australia to test this type of intervention and measure its
impact on healthcare consultations. Information from
this trial will enable planning of a larger phase III inter-
national trial to further assess the impact of the CHEST
Intervention on clinical outcomes.
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